Ulotaront is an agent that acts as a ”trace amine-associated receptor 1” (TAAR1) agonist with 5-HT1A agonist activity, showing promising but preliminary results in the treatment of schizophrenia, free of extrapyramidal symptoms or metabolic side effects [51]. This evidence concerns the gene HTR1A and schizophrenia.